Latka logo

How Enzyme CEO Jared Seehafer grew Enzyme to $10.3M revenue and 21 customers in 2024.

Automating FDA approval and compliance

Last updated

Enzyme Revenue

In 2024, Enzyme's revenue reached $10.3M. The company previously reported $6.5M in 2023. Since its launch in 2018, Enzyme has shown consistent revenue growth.

Enzyme Revenue GrowthReported revenue / ARR by year$0$3M$5M$8M$10M$13M2018201920202021202220232024$1M$6M$10MSource: GetLatka.com interview on Dec 3, 2018 with Enzyme CEO Jared Seehafer
YearMilestone
2024Enzyme Hit $10.3m revenue in October 2024
2023Enzyme Hit $6.5m revenue in December 2023
2018Enzyme Hit $1.1m revenue in December 2018
2018Launched with $0 revenue

Enzyme Valuation, Funding Rounds

Enzyme has not publicly disclosed its valuation. The company has raised $2M in total funding to date.

Enzyme has raised $2M in total funding across 2 rounds, most recently a $1.9M Seed Round round in 2017.

Enzyme Capital Raised & ValuationCumulative capital raised and post-money valuation by roundCapital raised (cum.)Valuation$0$500K$1M$2M$2M$3M201720182017 cumulative: $120K • 2017 Pre Seed Round: $120K2017 cumulative: $2M • 2017 Pre Seed Round: $120K • 2017 Seed Round: $2M2018 cumulative: $2M • 2017 Pre Seed Round: $120K • 2017 Seed Round: $2M • 2018 Founded: $0$2M2018 Founded: $0 valuationSource: GetLatka.com interview on Dec 3, 2018 with Enzyme CEO Jared Seehafer
YearRoundAmountValuation% Sold
2017Seed Round$1.9M--
2017Pre Seed Round$120K--

Enzyme Employees & Team Size

Enzyme employs approximately 33 people as of 2026.

Enzyme has 33 total employees in different roles and functions. They have 21 customers that rely on the company's solutions.

Enzyme Team GrowthReported headcount over time08152330382018201920202021202220232024773333Source: GetLatka.com interview on Dec 3, 2018 with Enzyme CEO Jared Seehafer
YearMilestone
2024Reached 33 employees (October 2024)
2023Reached 33 employees (December 2023)
2022Reached 27 employees (December 2022)
2021Reached 19 employees (December 2021)
2020Reached 18 employees (December 2020)
2020Reached 19 employees (June 2020)
2018Reached 8 employees (December 2018)
2018Reached 7 employees (December 2018)

Founder / CEO

Jared Seehafer

Jared Seehafer is the CEO and Cofounder of Enzyme, a software company that automates life science regulatory approval and compliance. He is a 12 year veteran of the medical device and biopharma industries, having worked or consulted at organizations ranging from Amgen, Abbott and Medtronic to seed-stage startups.

Q&A

QuestionAnswer
What's your age?36
Favorite online tool?-
Favorite book?-
Favorite CEO?-
Advice for 20 year old self-

Customers

See how Enzyme acquires and retains customers with data on acquisition costs and revenue performance. Log in to access the complete customer economics dashboard.

Locked

Frequently Asked Questions about Enzyme

What is Enzyme's revenue?

Enzyme generates $10.3M in revenue.

Who founded Enzyme?

Enzyme was founded by Jared Seehafer.

Who is the CEO of Enzyme?

The CEO of Enzyme is Jared Seehafer.

How much funding does Enzyme have?

Enzyme raised $2M.

How many employees does Enzyme have?

Enzyme has 33 employees.

Where is Enzyme headquarters?

Enzyme is headquartered in San Francisco, California, United States.

People Also Viewed

Sales Layer logo

Sales Layer

Developer of an information platform created to improve product management process. The company's platform uses analytics and automation to centralizes data and synchronizes it in all sales channels automatically to optimizes the management for all types of companies regardless of their size, sector or type, enabling brands and retailers to increase their sales by improving their content across multiple interfaces and multiple sales channels.

Rand Labs logo

Rand Labs

A blockchain development lab specialized in Algorand technology. Our Products: AlgoExplorer My Algo Incubation Labs: Professional development services [email protected]

Fadada.com logo

Fadada.com

Operator of an electronic contracts service platform. The company provides an online platform for electronic document signing and certificate services such as electronic contracts signature, documents signature, evidence custody and other electronic related signature.

Scalesource logo

Scalesource

Scalesource is a platform that provides virtual recruiters as a more cost-effective alternative to traditional in-house recruiters. Our service significantly reduces staffing expenses and enhances human resource management efficiency.

POC Pharma logo

POC Pharma

POC Pharma is a SaaS Company supporting pharma stakeholders to digitally manage their interactions, and grow faster and cheaper.

OnSeen logo

OnSeen

Developer if mobile workforce management software intended to manage people, places and assets. The company's platform schedules, dispatches, monitors and task remote staff and contractors, provide real-time status updates to everyone involved in the process and collaborate with mobile resources in real-time, enabling clients to optimize their processes and reduce their project costs.

Compare Enzyme to the industry

Enzyme operates across multiple industries. Browse revenue, funding, and growth data for Enzyme in each sector below.

Full Interview Transcript

Read transcript

hello everyone my guest today is jared seyhofer he is the ceo and co-founder of enzyme a software company that automates life science regulatory approval and compliance he's a 12-year veteran of the medical advice and biopharma industries having worked or consulted at organizations ranging from amgen abbott and medtronic to seed sage startups jared are you ready to take us to the top let's do it all right complex space here help us understand what you do and how you make money sure thing so if you are a company making life science technology this is going to be drug medical device diagnostic something like an mri a pill anything that is used in the practice of medicine besides a doctor uh or a nurse kind of rendering professional judgment uh there's a complex regulatory pathway you have to go through and it's different for every country in the united states that's the fda most people are familiar with that but every every geography has its own version of the fda on the market you have to go through a number of complex regulatory processes these are steps you have to do where you essentially present a case to the government as to why your product is quote safe and effective it both is safe to the user for its use and it's also going to do what you say it's going to do so you can't sell snake oil and that's it's a it's a complex process and if you're a large company uh you generally just hire an army people who are expert in doing this process it's a whole professional organization with its own um you know its own career path but if you're a smaller organization that can be very challenging because it's expensive and so if you're a little startup you've got this great new product great new idea you want to see it uh you're you're talking and spending hundreds of thousands of dollars in addition to the development cost of your product for your product to ever see the light of day and so what we're trying to do at enzyme is to use software to radically simplify the amount of human labor that goes into making all of this documentation that the government needs to say yes or no okay and pricing model is it pure place ass or exactly yeah so we we have a they're essentially uh an ongoing sas relationship with our customers sometimes with some add-on services depending what they need do they need a human voice in front of fda that kind of thing but it's generally a sas product yep okay and help me understand i mean generally speaking are we talking people paying you a grand a month or 10 grand a month or a million a month what scale are you playing at yeah so it's uh anywhere depending on company size from a five figure to a seven figure a year type of situation and we we try to bias it based on company size number of products they're doing uh etc so that we're offering something that is not only delivering kind of price relative to value but there's also something very achievable and represents a cost savings for wherever you are so if you know if you're a small company you'd be spending you know six figures in labor on this we're trying to get under that if you're a large company it's a huge expenditure give me just because we don't have enough time to learn every cohort give me the sweet spot i mean this is 50 000 bucks a year i mean is that a fair kind of sweet spot target for you if you were doing a garage startup that would be exactly it yep okay okay fair enough good and then put this on on a timeline for us when did you launch the company what year so we we uh we were in sort of quasi-stealth though i hate the term of 20 um in 2017 launched the company earlier this year in 2018 q1 okay 2018 launched the company and i mean so why get by the way why get into this space this is like many people would say boring and it's like the government and hipaa and not fun i mean why get into this so it's a personal pain for me because i spent my career actually being a biomedical engineer so my background is in very very complicated uh medical devices that treat neurological disorders did graduate work in doing deep brain stimulation for parkinson's disease i tell your listener base if you ever want to see a miracle uh in real life go youtube or google dbs that's uh d a b s d brain simulation for parkinson's and you'll watch something that you do not believe someone is literally doing tremors they cannot move someone flicks a switch and all of a sudden they walk as if they have no problem so i got into this space really wanting to use technology to transform people's lives uh and their health and what i found is being an engineer um that it would take forever to get your products on the market and it was very expensive and you saw a lot of failures that weren't necessarily related to whether the product was any good or not or did what you said and so i'm trying to scratch my own ish i'm trying to solve and solve problems and and uh create the kind of uh software that i wish i had had as someone building life-saving technology yep yep okay very good so kind of stealth last year you launched this year what have you scaled to today in terms of total customers using the platform so we've got 21 companies that are using the platform in production of various sizes everything from sort of you know product teams to large organizations enterprise organizations to like i said kind of a garage startup okay and 21 paying a 50 000 ac that puts you right at that nice million dollar run rate i mean have you guys passed that at this point uh yeah we're right around there that's great congratulations and a year ago nothing right a year ago we were doing essentially very uh uh you know small amount kind of early adopter yeah what are you talking like five grand a month yeah yeah well exactly you were talking um not even like 15 20 yeah 100 yeah 20 exactly yeah uh very good all right and how did you i mean walk me through how you landed the first customer so it was it was actually quite by uh random um chance uh it was in uh it just kind of started working on the product as a product as a side project for my consulting business and uh went to on a lark uh jason calacanis's launch um one of the launch events in san francisco here and i'm just uh walking around the uh the little stalls and uh just looking at interesting biological products and i really found one and uh it was one of these things where i was asking just asking questions and it turned out the ceo of the company he's like you seem to know a lot about this what do you do for opening night you know i mentioned we started the company it's like it just so happens we've had this problem we've been going through consultants you know we uh you know we we hate dealing with them they're way too expensive not a whole lot of value i love a software-based solution let's go demo the product and the pro my heart kind of stopped it was like this is all right at the launch event yeah exactly it's happening all basically sort of in the space 15 minutes um it had the demo the product was a total mess but it was it was doing enough that they found it valuable and we've been working with it ever since interesting talk to me about how you've capitalized the company so have you bootstrapped to raise capital we went through uh the y combinator accelerator uh you know did a small friends and family round uh kind of just when i was just getting started um then went through yc and then raised uh uh seed stage round of capital um you know through various vcs that are kind of in that at that cohort uh right after yc so all in today what a million two million something like that a couple million yeah a couple million okay very good um you've i assume you've done a price drone at this point right or is it all still debt convertible uh so the standard out here these days is just is the sort of safe type of model so we've been following that yeah okay so you haven't you have all the all the couple million has been all on the safe they haven't raised a price round yet right okay very good and help me understand kind of what you've scaled team to how many people yeah so we've got uh eight people on staff here we've uh various um kind of makes up developers and sort of regulatory experts all in san fran yeah no we do a mix of sf and remote i basically kind of found like a lot of uh we found a lot of entrepreneurs out here it's just that the cost of living situation has sort of made it advantageous to really trying to make a quasi-remote organization from the ground up yeah have you been able to dial in yet some of the other economics around you know driving customer growth related to like you know churn expansion revenue kak or is it really too early your cohort's too small well so for the nature of our business is such that uh we don't really see churn churn for us is is a customer getting bought or acquired and so what about what's approved what if your thing works and what if your thing works and it might think it's approved why do i still need you ah because it's it's actually that's a really good question um most people think of these things as binary and in you know or event driven so my product gets approved i don't need an fda person anymore what most people don't realize about life science regulations is pervasive throughout the life of the company so think of it a little bit like event driven but...

This is an excerpt. The full unedited transcript is available through GetLatka exports.

Source Attribution

Source: all data was collected from GetLatka company research and founder interviews. Revenue, funding, team, and customer figures are presented as company-reported or GetLatka-estimated metrics where the profile data identifies them that way.

Company data last updated .

Enzyme Revenue 2024: $10.3M ARR, $2M Raised